Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

21.1%

4 terminated/withdrawn out of 19 trials

Success Rate

76.5%

-10.0% vs industry average

Late-Stage Pipeline

26%

5 trials in Phase 3/4

Results Transparency

108%

14 of 13 completed trials have results

Key Signals

2 recruiting14 with results

Enrollment Performance

Analytics

Phase 1

8(42.1%)

Phase 2

6(31.6%)

Phase 3

5(26.3%)

19Total

Phase 1(8)

Phase 2(6)

Phase 3(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials

NCT06504381Phase 1Recruiting

DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

Role: collaborator

NCT06264388Phase 2Recruiting

DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

Role: collaborator

NCT05113771Phase 2Completed

A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD

Role: lead

NCT03263026Phase 3Completed

Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™

Role: lead

NCT03776071Phase 3Completed

A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

Role: lead

NCT01606436Phase 1Completed

A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia

Role: lead

NCT00845026Phase 2Completed

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

Role: lead

NCT01307800Phase 3Terminated

A Study of LY2140023 in Patients With Schizophrenia

Role: lead

NCT01452919Phase 3Completed

A Physical Dependence Study in Schizophrenia

Role: lead

NCT01354353Phase 1Completed

A Study of Safety and Tolerability in Subjects With Schizophrenia

Role: lead

NCT01328093Phase 3Terminated

A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

Role: lead

NCT01052103Phase 2Completed

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

Role: lead

NCT01475136Phase 1Completed

A Study of LY2140023 in Hepatically-Impaired Participants

Role: lead

NCT01609218Phase 1Completed

A Study of LY2140023 in Healthy Participants

Role: lead

NCT01591330Phase 1Completed

A Study of LY2140023 in Healthy Males and Females

Role: lead

NCT01637142Phase 1Completed

A Study of LY2140023 in Healthy Participants

Role: lead

NCT01125358Phase 2Terminated

A Study in Schizophrenic Patients

Role: lead

NCT01659177Phase 1Withdrawn

A Study of LY2140023 in Healthy Participants

Role: lead

NCT00149292Phase 2Completed

Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo

Role: lead

All 19 trials loaded